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Abstract  
Hydrogen sulfide (H2S), carbon monoxide (CO) and nitric oxide (NO) share signaling and vasorelaxant 
properties and are involved in proliferation and apoptosis. Inhibiting NO production or availability induces 
hypertension and proteinuria, which is prevented by concomitant blockade of the H2S producing enzyme 
cystathionine γ-lyase (CSE) by D,L-propargylglycine (PAG). We hypothesized that blocking H2S 
production ameliorates Angiotensin II (AngII)-induced hypertension and renal injury in a rodent model. 
Effects of concomitant administration of PAG or saline were therefore studied in healthy (CON) and AngII 
hypertensive rats.  
In CON rats, PAG did not affect systolic blood pressure (SBP), but slightly increased proteinuria. In AngII 
rats PAG reduced SBP, proteinuria and plasma creatinine (180±12 vs. 211±19 mmHg; 66±35 vs. 346±92 
mg/24h; 24±6 vs. 47±15 µmol/L, respectively; p<0.01). Unexpectedly, kidney to body weight ratio was 
increased in all groups by PAG (p<0.05). Renal injury induced by AngII was reduced by PAG (p<0.001). 
HO-1 gene expression was increased by PAG alone (p<0.05). PAG increased inner cortical tubular cell 
proliferation after 1 week and decreased outer cortical tubular nucleus number/field after 4 weeks. In vitro 
proximal tubular cell size increased after exposure to PAG. 
In summary, blocking H2S production with PAG reduced SBP and renal injury in AngII infused rats. 
Independent of the cardiovascular and renal effects, PAG increased HO-1 gene expression and kidney 
weight. PAG alone increased tubular cell size and proliferation in-vivo and in-vitro. Our results are 
indicative of a complex interplay of gasotransmitter signaling/action of mutually compensatory nature in 
the kidney.  
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1. Introduction 
Hydrogen sulfide (H2S) is the third gasotransmitter, in addition to nitric oxide (NO) and carbon monoxide 
(CO), and all three are involved in similar physiological processes [1]. H2S is endogenously produced in 
mammalian cells [2] and catalyzed from L-cysteine by the enzymes cystathionine β-synthase (CBS), 
cystathionine γ-lyase (CSE) and 3-mercaptopyruvate sulfur transferase (MST) [3; 4; 5]. CSE is mainly 
responsible for H2S synthesis in the kidney, liver, and vascular endothelium and smooth muscle cells [1; 
6], while CBS and MST account for the majority of H2S generation in the nervous system [7]. CSE derived 
H2S synthesis can be inhibited with DL-propargylglycine (PAG) [8; 9] or by genetic deletion of CSE [10; 
11]. 
The role of H2S as a vasodilator is well documented [1], but H2S seems to act in a bell-shaped fashion; 
causing vasoconstriction at low concentrations, vasorelaxation at higher concentrations, and toxicity at 
even higher concentrations [4]. Increasing H2S availability by two different H2S donors decreased blood 
pressure and improved renal function and morphology in Angiotensin II (AngII)-infused rats [12]. Inhibiting 
H2S synthesis by administration of both PAG and aminooxyacetic acid (AOA), a CBS blocker, increased 
mean arterial pressure (MAP) and decreased renal blood flow without affecting glomerular filtration rate 
indicating post-glomerular vasoconstriction while treatment with only one of these enzyme blockers did not 
affect MAP and renal function in healthy rats [13]. Pretreatment of rats with PAG caused an increased 
infarct size after myocardial ischemia induced by vasoconstriction [14]. However, hypertension and 
proteinuria caused by blocking NO synthesis could be prevented by concomitant PAG administration [15]. 
Thus the effects of modulating endogenous H2S levels are inconsistent and might be concentration and 
cell type or organ dependent. As a result, the functions of endogenously produced H2S in the healthy and 
diseased kidney are not well understood. In renal ischemia/reperfusion injury, inhibition of H2S synthesis 
increased plasma creatinine values and mortality [10], while in toxic kidney injury, inhibiting H2S synthesis 
reduced plasma creatinine and improved morphology. The latter effect was possibly caused by a 
reduction in inflammation [16; 17; 18]. Blocking H2S production resulted in an increase in CO production 
in-vivo [15] and in-vitro [19]. Similar in-vivo effects on CO production were observed when H2S inhibition 
was combined with NO synthase blockade [15]. Remarkably, H2S donors are also able to increase heme-
oxygenase-1 expression (HO-1) [20; 21]. Because all three gasotransmitters have vasodilatory properties 
[1], it is possible that CO can compensate for diminished H2S or NO production. 
Besides regulating vascular tone, H2S is also involved in cellular processes like proliferation [22] and 
protein synthesis and thereby cellular hypertrophy [23]. H2S can have inhibitory as well as stimulatory 
effects on proliferation. Inhibition of proliferation was observed in HEK-293 cells and smooth muscle cells 
overexpressing CSE and apoptosis was increased under these conditions [24; 25]. In CSE gene knockout 
mice, proliferation of aortic smooth muscle cells was increased compared with wild-type mice. Lowering 
blood pressure did not affect proliferation [26]. However, Bos et al. [10] reported that proliferation was not 
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affected in kidneys of CSE gene knockout mice. Furthermore, tubular proliferation was found to be 
decreased by PAG in adriamycin-induced kidney injury [17].  
We sought to study the effects of H2S inhibition on renal morphology and function in healthy rats and in a 
hypertensive renal injury model caused by AngII infusion. Based on our previous finding that PAG 
ameliorated hypertension and renal injury induced by NO inhibition [15], we hypothesized that PAG also 
decreases blood pressure and ameliorates renal injury in the AngII model. Moreover, because we found 
PAG to enhance renal mass and affect cell proliferation, we also studied effects of PAG on epithelial cell 
number and size in-vivo and in-vitro.  
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2. Materials and methods 
2.1 Animals 
Male Sprague-Dawley rats (261±20 gram, Harlan, Blackthorn, UK or Zeist, the Netherlands) were housed 
in a light-, temperature- and humidity controlled environment under standard conditions i.e. a 12 hour 
light/dark cycle and with free access to water and standard rodent chow. Protocols were approved by the 
Animal Ethics Committees of Utrecht University and the University of Groningen. Animal experiments 
were performed according to ARRIVE guidelines. 
2.2 Experimental setup 
PAG (dissolved in saline 30 mg/mL, 37.5 mg/kg BW) was administered daily intraperitoneally (ip) for one 
or four weeks in healthy rats (n=6, CON + PAG), while healthy saline treated rats served as control group 
(n=6, CON) as previously described [15]. Hypertension-driven renal injury was induced by AngII infusion 
(435 ng/kg/min, Bachem, Weil am Rhein, Germany) for three weeks via a subcutaneous osmotic 
minipump (model 2004, Alzet, Cupertino, CA) which were implanted under isoflurane anesthesia with 
buprenorphine analgesia [12]. As a control for AngII infusion, saline-filled minipumps were implanted in a 
group of rats (n=5, VEH). AngII-infused rats were randomly divided over intraperitoneal injections with 
saline (saline twice daily, n=7; AngII) and PAG (18.75 mg/kg twice daily ip, n=7; AngII + PAG).  At the end 
of the experiment rats were sacrificed, a blood sample was taken and kidneys were excised, weighed, 
fixed in formaldehyde and then embedded in paraffin or snap frozen and stored at -80°C for RNA 
isolation. 
2.3 H2S production in kidney 
Renal H2S production was measured exactly as previously described [15]. For all samples 5% (w/v) renal 
homogenates were used for measurements. 
2.4 Kidney function and systolic blood pressure 
Systolic blood pressure (SBP) was measured and a blood sample was collected before sacrifice. 24-hour 
urine samples were collected weekly (except week 3 for 4wk CON rats) by placing rats individually in 
metabolic cages without chow but with free access to glucose-containing water (2% w/v). Urine was 
collected on antibiotics to prevent formation of NO metabolites and frozen after collection. In CON groups, 
total protein excretion was measured using Bradford method (BioRad Laboratories, Veenendaal, 
Netherlands) and plasma creatinine was enzymatically measured (DiaSys PAP FS; DiaSys Diagnostic 
Systems, Holzheim, Germany). In VEH and AngII groups, total protein excretion was measured using 
pyrogallol red molybdate method [27] and plasma creatinine was measured on the Roch Modular with a 
standard assay from Roche (Roche Diagnostics GmbH, Mannheim, Germany). SBP was measured by tail 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
6 
 
cuff sphygmomanometry (CON groups) or via an intra-aortic probe before sacrifice (VEH and AngII 
groups).  
2.5 Urine malondialdehyde 
Malondialdehyde (MDA) is a major breakdown product of lipid peroxides, which is generated under 
conditions of oxidative stress and can be measured fluorimetrically following reaction with thiobarbituric 
acid. A total of 20 µL urine was mixed with 90 µL of 3% SDS and 10 µL of 0.5 M butylated hydroxytoluene 
followed by addition of 400 µL 0.1N HCl, 50 µL 10% phosphotungstic acid and 200 µL 0.7% 2-
Thiobarbituric acid. This reaction mixture was incubated for 30 minutes at 95°C. After addition of 800  µL of 
1-butanol, samples were centrifuged at 960g for 10 minutes. The supernatant was fluorescently measured 
at 530 nm excitation and 590 nm emission. 
2.6 NO metabolites 
Both urine and plasma samples were added to equal volumes of methanol, vortexed, and centrifuged at 
16100g on 4ºC for 20 min. The supernatant was transferred to autosampler vials and oxidation products of 
nitric oxide (nitrite and nitrate) were quantified by high pressure liquid ion chromatography with on-line 
reduction of nitrate to nitrite and post-column derivatisation with the Griess reagent (ENO-20 Analyser; 
Eicom, San Diego, CA) [28; 29]. For some urine samples, a further dilution with PBS (10 mM, pH 7.4) was 
required to stay within the linear part of the standard curve. Fractional excretions of nitrite and nitrate were 
calculated using the following formula: urine NOx*plasma Creatinine/plasma NOx*urine Creatinine. All 
concentrations in µM.  
2.7 Quantitative polymerase chain reaction 
Renal cDNA was isolated to determine gene expression of CSE, CBS and HO-1 using qPCR (ViiA7 Real-
Time PCR system, Life technologies, Waltham, MA). The following TaqMan Gene Expression Assays 
(Applied Biosystems, Foster City, CA) were used: CTH (Rn00567128_m1), CBS (Rn01428016_m1) and 
HO-1 (Rn00561387_m1). Cycle time (Ct) values for CBS, CSE and HO-1 were normalized for mean Ct-
values of ACTB (Rn00667869_m1) and CANX (Rn00596877_m1) or HPRT (Primers (Integrated DNA 
Technologies, Coralville, IA, USA) Forward: 5'-GCC CTT GAC TAT AAT GAG CAC TTC A-3’, Reverse: 5'-
TCT TTT AGG CTT TGT ACT TGG CTT TT-3’ and Probe (Eurogentec, Maastricht, the Netherlands): 6-
FAM 5'-ATT TGA ATC ATG TTT GTG TCA TCA GCG AAA GTG-3' TAMRA.), and expressed relative to 
their own control groups using the ∆∆Ct method. 
2.8 Renal morphology 
Three µm sections were sliced of formaldehyde-fixed, paraffin-embedded kidneys. Sections were stained 
with primary antibodies for desmin (mouse anti-desmin NCL-DES-DER11, 1:500, Novacastra, Rijswijk, the 
Netherlands), Kidney Injury Molecule 1 (KIM-1, rabbit anti‐Kim‐1 peptide 9, 1:400, gift V. Bailly, BiogenInc, 
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Cambridge, MA, USA), ED-1 (mouse anti-CD68 ED-1, MCA341R AbD, 1:750, Serotec Ltd, Oxford, UK), 
α-Smooth Muscle Actin (α-SMA, mouse anti‐SMA, clone 1A4 A2547, 1:10.000, Sigma, Zwijndrecht, the 
Netherlands), Collagen III (goat anti‐type III Collagen, 1330‐01, 1:75, Southern Biotech, Birmingham, AL, 
USA), Ki67 (rabbit anti-Ki67, RM-9106, 1:100, Fisher Scientific, Waltham, MA) and Podoplanin (mouse 
anti-Podoplanin, 11-035, Angio Bio, Del Mar, CA). Deparaffinized sections were subjected to heat-induced 
antigen retrieval by overnight incubation with 0.1 M Tris/HCl buffer (pH 9.0) at 80°C (desmin, KIM-1, ED-1, 
αSMA) or by incubation with EDTA buffer (pH 8.0) heated by a microwave (Collagen III) or by incubation 
with citrate/HCl buffer (pH 6.0) at 100°C for 20 mi nutes (Ki67, Podoplanin). Kidney sections were scanned 
using an Aperio Scanscope GS (Aperio Technologies, Vista, CA, USA). The extent of glomerular damage 
(desmin), proximal tubular ischemic damage (KIM-1) and fibrotic changes (α-SMA, Collagen III) were 
determined using the Aperio positive pixel analysis v9.1 algorithm. For desmin the ratio between 
glomerular staining intensity and total cortical glomerular area was calculated. For KIM-1, α-SMA and 
Collagen III the ratio between the relative cortical staining intensity and the total cortical surface area was 
used. Interstitial macrophages were counted manually in 30 renal cortical high powered fields (HPF). 
Tubular lumen area was measured in cortical tubular fields, ten fields of similar size were selected and 
transformed to 8-bit, a threshold was set, pictures were inverted and the percentage black area was 
measured using ImageJ software (Rasband, W.S., ImageJ, NIH, Bethesda, MY). In 10 and 5-8 tubular 
fields in the outer and inner cortex of CON rats nuclei were counted using ImageJ. Proliferating cells 
(Ki67) were counted in 10 and 5-8 tubular fields in the outer and inner cortex to detect epithelial 
proliferation. Lymph vessels were stained by Podoplanin and counted in 30 cortical fields, size of 
individual lymph vessels was measured as perimeter with ImageJ software. Lymph vessel perimeters 
were categorized by size in extra small, small, medium and large vessels [30]. Histological analysis was 
performed in a blinded fashion. 
2.9 In-vitro assay 
Human proximal tubule epithelial (HK-2) cells [31] were cultured in RPMI + GlutaMax containing 10% 
FCS, 1% penicillin/streptomycin and 25 mM Hepes. HK-2 cells (60% confluency) were serum starved (1% 
FCS) for 24 hours before adding PAG (1 and 3 mM). After 48 hours cells were trypsinized and cellular size 
was measured by forward scatter (FSC) using flow cytometry. Histograms of cell counts were made to 
discriminate between small and large cells and the percentage of large cells was calculated. Cellular 
surface area was measured on immunofluorescent labeled cells. Accordingly, cultured cells were fixed 
with 4% paraformaldehyde on coverslips. Cellular membranes were labeled with Beta-catenin (9582, 
1:100, Cell Signaling, Danvers, MA). Rhodamine Phalloidin (R415, 1:40, Life Technologies, Waltham, MA) 
and DAPI were used to label actin filaments and nuclei respectively. Cellular size of 50 cells was 
measured using ImageJ software. 
2.10 Statistical analysis 
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Data are presented as mean ± standard deviation (SD). A two-way ANOVA with Student–Newman–Keuls 
(SNK) as post-hoc test was performed using SigmaPlot 12.3 (Systat Software Inc., San Jose, CA) on 
CON and CON + PAG groups. VEH, AngII and AngII + PAG groups were compared using a one-way 
ANOVA with SNK as post-hoc test, when only AngII and AngII + PAG rats were included a t-test was 
performed. In-vitro data was tested using a one-way ANOVA with Dunnett’s as post-hoc test. P<0.05 was 
considered significant, p>0.05 non-significant (NS). 
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3. Results 
 
3.1 PAG abolished H2S production 
H2S production in the kidneys of PAG treated rats was abolished in both CON (p<0.001) and AngII 
(p<0.05) groups. AngII markedly decreased H2S production compared to VEH rats (p<0.01; figure 1).  
 
Figure 1. H2S production in kidneys of healthy, AngII and PAG treated rats. Mean ± SD. All n=3. *p<0.05, 
**p<0.01, *** p<0.001 
 
3.2 PAG improved systolic blood pressure and kidney function in AngII-infused rats 
AngII infusion increased SBP and plasma creatinine measured at week 3 and proteinuria at all weeks 
compared to VEH rats (p<0.01; table 1). PAG blunted this increase in SBP and reduced plasma creatinine 
(p<0.01; table 1). At weeks 2 and 3 PAG markedly reduced AngII-induced proteinuria, with a respective 
median and range of 54 [20-115] vs. 329 [235-513] mg/24h at week 3. PAG administration in CON rats did 
not affect SBP. Plasma creatinine was slightly increased after PAG in CON rats (table 1), but was not 
affected by the duration of PAG (1wk vs. 4wk, NS). In CON + PAG rats proteinuria was already slightly 
higher at baseline compared to CON. Proteinuria increased slightly in both CON and 1wk CON + PAG 
rats during the course of one week. However, proteinuria was not progressive during a four week period of 
PAG (table 1). AngII increased urinary MDA excretion, a measure of oxidative stress, compared with VEH 
rats, and AngII induced oxidative stress was not affected by PAG (table 1). MDA excretion was increased 
by four weeks PAG compared to CON rats. 
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Table 1. Systolic blood pressure, plasma creatinine, proteinuria and MDA excretion in healthy, AngII and PAG treated 
rats. SBP and proteinuria of CON groups as published by Wesseling et al. [15]. 
 1wk  
CON 
1wk  
CON + PAG 
4wk  
CON 
4wk  
CON + PAG 
3wk  
VEH 
3wk     
AngII 
3wk         
AngII + PAG 
n= 6 6 6 6 5 6-7 7 
SBP (mmHg) 133 ± 24 135 ± 8 137 ± 7 133 ± 8 143 ± 5 211 ± 19bb 180 ± 12aa,bb 
Creatinine (µM) 26 ± 3 53 ± 12 a a 30 ± 3 41 ± 7 a
 
  19 ± 2 47 ± 15bb 24 ± 6aa 
Proteinuria 
(mg/24h) 
Baseline 
Week 1 
Week 2 
Week 3 
Week 4 
 
 
11 ± 6 
17 ± 6* 
 
 
24 ± 4a 
36 ± 3a,* 
 
 
9 ± 1 
13 ± 3 
13 ± 1 
 
17 ± 5* 
 
 
27 ± 6aaa 
34 ± 5aaa 
33 ± 3aaa 
 
30 ± 7aaa 
 
 
13 ± 8 
25 ± 14aa,* 
25 ± 17aaa,** 
28 ± 25aaa,* 
 
 
9 ± 3### 
80 ± 76### 
223 ± 74# 
346 ± 92#  
 
 
10 ± 2 
51 ± 35*** 
49 ± 37aaa,*** 
66 ± 35aaa,bb,*** 
MDA excretion 
(nmol/24h/100g) 
27 ± 10 34 ± 15 24 ± 10 36 ± 5a 20 ± 7 67 ± 15bb 60 ± 22bb 
 Mean ± SD. ap<0.05, aap<0.01 vs. 1wk or 4wk CON or AngII group, bp<0.05, bbp<0.01 vs. VEH, *p<0.05, **p<0.01, 
***p<0.001 vs. Baseline, #p<0.05, ###p<0.001 vs. all weeks 
 
3.3 PAG decreased plasma and urinary NO metabolites in healthy but not in AngII infused rats  
PAG decreased plasma nitrite concentrations (NO2-, p<0.001; figure 2A) and urinary NO2- excretion 
(p<0.001; figure 2B), as well as fractional NO2- excretion (FeNO2-, figure 2C; Two-way ANOVA PAG effect 
p<0.05). AngII increased NO2- excretion (p<0.05) and tended to increase FeNO2- (p=0.052), but did not 
affect plasma NO2- (figure 2A-C). No additive effects of PAG were observed concomitantly with AngII.  
Plasma nitrate (NO3-, figure 2D), NO3- excretion (figure 2E) and FeNO3- (figure 2F) all decreased after four 
weeks of PAG administration (all p<0.01). AngII increased plasma NO3- concentrations, but not NO3- 
excretion (figure 2D,E). PAG reduced AngII increased FeNO3- (p<0.05; figure 2F). 
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Figure 2. Plasma levels (A), renal excretion (B) and fractional excretion (C) of nitrite (NO2-)  and plasma levels (D), 
renal  excretion (E) and fractional excretion (F) of nitrate (NO3-) in healthy, AngII and PAG treated rats. Mean ± SD. 
1wk CON, 4wk CON and 4wk CON + PAG n=6, 1wk CON + PAG n=3, 3 wk VEH n=5, 3 wk AngII and 3 wk AngII + 
PAG n=7. *p<0.05, **p<0.01, *** p<0.001 
 
3.4 PAG increased HO-1 gene expression in healthy rats 
PAG increased HO-1 gene expression in CON rats at one and four weeks (p<0.05). AngII infusion also 
increased HO-1 gene expression vs. VEH rats (p<0.05), however this was not significantly affected by 
PAG (AngII vs. AngII + PAG, NS; figure 3A). Proteinuria correlated with HO-1 gene expression in CON, 
VEH and AngII rats without PAG (p<0.01), but this correlation was absent in CON and AngII rats with PAG 
(figure 3B). 
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Figure 3. Relative renal HO-1 gene expression in PAG and AngII treated rats normalized to their own healthy control 
group (A). B: Correlation of HO-1 gene expression with proteinuria for all VEH (n=24) and all PAG (n=16) rats. Mean ± 
SD. CON and CON + PAG groups n=6, VEH n=5, AngII and AngII + PAG n=7. *p<0.05,**p<0.01 
 
3.5 PAG reduced renal damage and inflammation in AngII-infused rats 
No glomerular tuft damage was observed in CON or CON + PAG rats (figure 4A). AngII induced 
glomerular tuft damage, which was reduced by PAG (700.3 ± 111.7 vs. 421.4 ± 116.0 intensity/µm2, 
p<0.01; figure 4A,B). Proximal tubular damage was also absent in CON and CON + PAG groups (figure 
4C), therefore these groups were not included for other morphological damage scores. PAG decreased 
proximal tubular damage caused by AngII infusion, as evidenced by a decreased KIM-1 protein 
expression (6 ± 4 vs. 14 ± 6 intensity/µm2, p<0.05; figure 4C,D). Furthermore, PAG reduced protein 
expression of α-SMA when compared to AngII-infused rats (6 ± 4 vs. 16 ± 5 intensity/µm2, p<0.05; figure 
5A,B) as well as Collagen III protein expression (16 ± 6 vs. 33 ± 9 intensity/µm2, p<0.05; figure 5C,D). The 
number of interstitial macrophages per field were doubled by AngII compared to VEH (204 ± 91 vs. 86  ± 
28, p<0.01), and PAG reduced macrophage numbers back to VEH level (40 ± 13 vs. 86 ± 28; figure 5E,F). 
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Figure 4. Glomerular tuft damage determined by desmin staining around the tuft edge (A) and proximal tubular 
damage determined by KIM-1 staining (C) in healthy, AngII and PAG treated rats. Representative photomicrographs 
of glomerular desmin (B) and KIM-1 (D) stained renal sections. Mean ± SD. VEH n=5, AngII and AngII + PAG n=7. 
*p<0.05, **p<0.01, ***p<0.001 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
14 
 
 
Figure 5. Pre-fibrotic interstitial damage determined by α-SMA staining (A), interstitial collagen determined by 
Collagen III staining (C) and interstitial macrophages determined by ED-1 staining (E) in healthy, AngII and PAG 
treated rats. Representative photomicrographs of α-SMA (B) Collagen III (D) and ED-1 (F) stained renal sections. 
Mean ± SD. VEH n=5, AngII and AngII + PAG n=7. *p<0.05, **p<0.01 
 
3.6 PAG increased kidney weight 
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Surprisingly, kidney weight to body weight (BW) ratio was increased after PAG treatment in all groups 
(figure 6A). This was already observed after one week of PAG in CON rats (0.36 ± 0.02 vs. 0.32 ± 0.01 
g/100g BW, p<0.01). The PAG-induced increase in kidney weight was not affected by the duration of PAG 
administration (1wk CON + PAG vs. 4wk CON + PAG, NS). AngII infusion increased kidney/BW ratio as 
compared to VEH rats (0.49 ± 0.02 vs. 0.38 ± 0.03 g/100g, p<0.01), and this was even further increased 
by PAG (0.49 ± 0.02 vs. 0.56 ± 0.07 g/100g, p<0.05). 
 
Figure 6. A: Kidney to body weight ratio in healthy, AngII and PAG treated rats. B: Tubular lumen area in healthy and 
AngII rats, saline or PAG treated. Mean ± SD. CON and CON + PAG groups n=5-6, VEH n=5, AngII and AngII + PAG 
n=6-7.  **p<0.01, ***p<0.001 
 
3.7 PAG decreased tubular cell number/field and increased tubular cell proliferation 
To study the cause of the increased renal weight elicited by PAG treatment tubular lumen area, nuclei 
number and proliferation were investigated. Tubular lumen area was not increased in PAG-treated 
compared to untreated rats (figure 6B). PAG decreased tubular nucleus numbers/field in the outer cortex 
in CON rats after one (990 ± 70 vs. 1106 ± 144) and four weeks (1021 ± 67 vs. 1161 ± 121, p<0.05; figure 
7A). In the inner cortex, PAG did not affect the number of tubular nuclei (figure 7B). As many inflammatory 
cells are present in kidney injury models that would result in unreliable automated counts of tubular nuclei 
tubular nuclei were only counted in CON rats. Tubular cell proliferation was not affected by PAG in the 
outer cortex for both CON and AngII groups. However, one week of PAG in CON rats considerably 
increased the proliferation of tubular cells in the inner cortex (84 ± 9 vs. 19 ± 2 Ki67+ cells/field, p<0.001), 
but not in 4wk CON + PAG and AngII rats (figure 8). 
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Figure 7. Tubular epithelial nucleus number per field in the outer cortex (A) and inner cortex (B) of healthy saline and 
PAG treated rats. Mean ± SD. CON and CON + PAG groups n=5-6. *p<0.05 **p<0.01  
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Figure 8. Tubular cell proliferation per tubular field in saline and PAG-treated rats (A) and representative 
photomicrographs of one or four week vehicle or PAG treated control rats in the outer cortex (left) and inner cortex 
(right) (B). Mean ± SD. CON and CON + PAG groups n=5-6. ***p<0.001 
 
3.8 PAG did not directly affect lymph vessels number and size 
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Disturbed lymphatic vessels function and/or number (assessed by counting the number and measuring 
the size of lymphatic vessels) may be a cause of fluid retention in the kidney resulting in increased kidney 
weight. Lymph vessel number was not affected by PAG in control rats (figure 9A). After AngII infusion 
PAG decreased the number of lymph vessels per tubular field (2.0 ± 0.4 vs. 3.8 ± 1.1, p<0.01). Lymph 
vessels categorized by size were not affected by PAG (figure 9B). 
 
Figure 9. Renal lymph vessel number (A) and size, displayed as percentage of very small, small, medium or large 
sized lymph vessels (B) in saline and PAG-treated rats. Mean ± SD. CON and CON + PAG groups n=4-6, AngII and 
AngII + PAG n=6-7. **p<0.01 
 
3.9 PAG increased cell size in-vitro 
Proximal tubular cells were cultured with 0 (CON), 1 or 3 mM PAG for 24 and 48 hours (figure 10A). After 
24 hours, no effect of PAG incubation on cellular size was observed (data not shown). However, after 48 
hours, the percentage of large cells measured by flow cytometry (figure 10B) increased after culturing with 
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3 mM PAG compared to 0 mM (73.6 ± 9.8 vs. 54.4 ± 4.6%, p<0.05). Increased cellular size was confirmed 
by enlarged surface area measured on fixed cells after 48h, at 1 and 3 mM PAG (figure 10C).  
 
 
Figure 10. A: Representative pictures of HK-2 cells incubated with PAG (0, 1 and 3 mM); green-cell membrane 
staining (beta-catenine), red-actin staining (phalloidin), blue-nuclear stain (DAPI). PAG dose-dependently increased 
cell size after 48 hours in-vitro as measured by flowcytometry (B). Cellular surface area increased after PAG 
incubation (C). Mean ± SD. n=3. *p<0.05, **p<0.01 
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4. Discussion  
The key findings of our study are 1) Inhibition of CSE-mediated H2S formation by PAG reduced blood 
pressure and proteinuria in AngII-infused rats, which was accompanied by less kidney injury and less 
morphological damage. 2) In CON rats and in rats with AngII-induced kidney injury, PAG increased kidney 
weight, independently of effects on SBP or kidney function, and structure including lymph vessel number 
and size. 3) There was a marked increase in proliferation in the inner cortex after one week of PAG. 
Finally, 4) in-vitro PAG exposure increased tubular epithelial cell size. 
H2S is mainly produced from L-cysteine and L-cystathionine via the enzymes CSE, CBS or MST [32; 33]. 
In the kidney, H2S is mainly produced by CSE, and renal CSE but not CBS correlates with kidney function 
after kidney transplantation [10]. Therefore, in the present study, we sought to inhibit CSE activity and 
thereby H2S production with PAG. PAG inhibits CSE by reacting with the pyridoxal-5’-phosphate (PLP) 
complex [9], although PAG is known to also react with other PLP dependent enzymes. In the present 
study we demonstrate complete blockage of H2S production in the kidney after PAG administration in 
healthy [15] and AngII-infused rats. As expected, AngII (without PAG) also decreased H2S production 
because of renal injury. The finding that PAG consistently abolished H2S production suggests that CBS 
and MST may also have been affected. Both the blood pressure reduction and the amelioration of renal 
injury by PAG treatment in AngII-infused rats are contradictory to our previous findings showing that 
exogenous H2S resulted in improvement of blood pressure and less renal injury in this model [12]. 
Moreover, endogenous H2S is important for vascular relaxation, by activating KATP channels on smooth 
muscle cells resulting in membrane hyperpolarization [34]. Although both, donating and inhibiting H2S, 
reduced blood pressure after AngII infusion, only exogenous H2S reduced oxidative stress. Reactive 
oxygen species (ROS) are known to be produced by AngII through NAPDH oxidase activation and ROS is 
probably a major player in the development of hypertension [35]. This suggests that the reduction in blood 
pressure by PAG is not directly ROS and AngII-mediated but is achieved via another pathway. During 
concomitant blockade of NO and H2S-synthesis we previously also observed a decrease in blood 
pressure and less proteinuria. This appeared to be related to increased CO production [15]. Hence in the 
present study we focused on HO-1, an enzyme that primarily catalyzes production of CO [1].  
It is known that AngII infusion in rats increases renal HO-1 expression [36; 37], which was confirmed in the 
present study. Increasing CO availability by the administration of an HO-inducer reduced blood pressure 
and renal injury caused by NO blockade or AngII infusion, whereas an HO inhibitor increased blood 
pressure and reduced renal function [36; 38; 39]. This corresponds to previous findings of Wesseling et al. 
[40] showing that inflammation and proteinuria caused by blocking NO synthesis correlates with HO-1 
gene expression. The slope of the expected positive correlation between renal HO-1 expression and 
proteinuria [40] was greatly diminished by PAG suggesting that the strong induction of HO-1 in PAG-
treated rats was directly caused by PAG. Reducing AngII- induced hypertension by losartan (an AngII 
receptor antagonist) also prevented an increase of HO-1 gene expression [37], suggesting that HO-1 gene 
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expression is also blood pressure or renal damage-dependent. This might also explain why we did not 
observe a further increase in HO-1 gene expression in animals simultaneously treated with AngII infusion 
and PAG.  
Blockade of H2S synthesis via CSE led to a decreased NO availability, judged by reductions in both 
circulating concentrations and urinary excretion of nitrite and nitrate. Together with the data on H2S 
production, these results strongly suggest that NO production, both systemically and in the kidney, is in 
part dependent on H2S production. In the presence of renal injury, a condition known to be associated with 
reduced whole body NO production [41; 42], in our study nitrite excretion increased while nitrate excretion 
did not change. This suggests intrarenal production of nitrate, perhaps by inflammatory cells; alternatively, 
nitrate secretion may be upregulated. Based on the marked increase in fractional nitrate excretion, the 
increase in plasma nitrate levels was at least partly a consequence of the fall in glomerular filtration.  
Besides amelioration of renal function by H2S donors in AngII infusion, tubular and glomerular damage 
and interstitial fibrosis were reduced [12]. However, in the present study inhibition of H2S resulted also in 
decreased glomerular and tubular damage. Reduced renal damage and proteinuria might be partly related 
to the decrease in blood pressure. PAG reduced blood pressure induced by NO synthesis blockade by 
15%, however proteinuria was reduced much more (81%) [15]. In AngII infused mice PAG did not affect 
the high blood pressure, but neither proteinuria nor renal damage were measured in this study [43]. Future 
work on the discrete effects of H2S and perhaps CO on intraglomerular hemodynamics and 
permselectivity may help to reconcile these findings. 
Although kidney function and tubular damage improved in AngII-infused rats, kidney weight increased 
after PAG treatment. This indicates that PAG or diminished H2S production by blockage of CSE affects 
cellular processes besides having functional effects in the kidney. An increase in kidney weight can be 
caused by several factors, including edema formation. PAG increased pulmonary edema and decreased 
the expression of AQP1/5 in rats with bilateral limb ischemia [44]. One of the most important causes of 
edema is hampering the crucial physiological function of lymphatic vessels in controlling tissue fluid 
balance and hemostasis, which can result in renal edema [45], and consequently can increase kidney 
weight. However, in our study renal lymphatic vessel function (number and/or size) was not affected after 
PAG treatment. Probably the increase in lymph vessel number (lymphangiogenesis) and size in AngII-
infused rats is caused by proteinuria as this has also been reported in adriamycin-induced CKD with 
protein excretion higher than 200mg/24h [30]. Furthermore, no tubular dilation was observed suggesting 
that obstruction of nephrons or the urinary tract was not involved. 
Increase in cellular size may be another factor involved in the enhanced kidney weight observed. In-vivo, 
the decrease in tubular nuclei/field in the outer cortex after PAG may explain the increase in cellular size. 
This effect was supported by an increase in size of HK2 proximal tubular cells in-vitro. This effect may not 
be restricted to the renal epithelium, because heart weight of PAG treated mice with myocarditis was 
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demonstrated to increase [46], while H2S donors reduced heart weight and cardiomyocyte size [46; 47]. 
Remarkably, our findings clearly dissociate kidney size from kidney injury in this model. 
Although no differences were observed in electrolyte excretion between vehicle and PAG treated rats, 
disturbances of ion channels may result in increased cellular tonicity, resulting in larger cells. Both, 
osmotic swelling and hypertrophy could increase cellular size. Little is known on effects of H2S or inhibition 
of H2S on cellular size. Glucose-induced hypertrophy and protein synthesis of glomerular epithelial cells 
was reduced by an H2S donor, but no effect was observed in healthy cells after incubation with an H2S 
donor [23]. This might suggest that subnormal H2S concentrations or CSE activity result in loss of control 
of protein synthesis, where in CSE-/- mice cysteine depletion led to hypermetabolism and enhanced insulin 
sensitivity. Weight loss could be restored by cysteine supplementation, but not by an H2S donor 
suggesting a H2S independent role of cysteine in metabolism [48]. 
Increased proliferation might also cause a larger kidney and thereby increase kidney weight. Tubular 
proliferation in the inner cortex was increased after one, but not after four weeks of PAG treatment. 
Incubation of glomerular mesangial cells with PAG resulted in increased proliferation [49], however in 
embryonic kidney cells overexpressing CSE, proliferation was also increased [24]. This indicates that 
effects of H2S on proliferation, at least in the kidney, are probably time and cell type dependent, and the 
increase in tubular cell size and proliferation may be a fast but not progressive effect of PAG, mediated 
directly by diminished H2S production.  
In conclusion, the CSE inhibitor PAG reduced AngII induced hypertension and ameliorated AngII induced 
renal injury in rats. PAG also increased kidney weight independently of effects on SBP and renal function. 
More studies with different models of CKD are required to fathom the role of endogenous H2S and CO in 
the kidney in order to understand how inhibition of H2S production as well as administration of H2S donors 
can show similar results in some models of renal injury. More research is also needed to define the 
pathways involved in PAG-induced cell enlargement and proliferation.  
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